Virtual Library
Start Your Search
Weijia Huang
Author of
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR (ID 253)
- Event: WCLC 2020
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P76.92 - TKI and Intrathoracic Perfusion in First-line Stage IV Lung Adenocarcinoma with EGFR Mutation and Malignant Pleural Effusion (ID 3687)
00:00 - 00:00 | Presenting Author(s): Weijia Huang
- Abstract
Introduction
Malignant pleural effusion(MPE) is one of the most common complications in advanced lung cancer which predicts worse prognosis. Advanced lung adenocarcinoma with EGFR sensitive mutation have been proved to be sensitive to tyrosine kinase inhibitor(TKI) treatment. However, TKI seems not so efficient in controlling MPE, thus significantly shorten patients’ survival. Here we compared prognosis of TKI treatment with/without intrathoracic perfusion in patients with treatment-naive stage IV lung adenocarcinoma with EGFR mutation and MPE.
Methods
Patients who were diagnosed with previously untreated stage IV lung adenocarcinoma with MPE were identified, in which only with EGFR sensitive mutation were selected, in Lung Cancer Center and Thoracic Oncology department, West China Hospital of Sichuan University from February 2012 to October 2018. The study population was divided into two cohorts with respect to received treatment, patients with TKI treatment alone(TKIs) or TKI along with concomitant intrathoracic perfusion(TKIs+ITP). The follow-up was performed via telephone and overall survival(OS) was calculated. The difference of efficacy of TKIs and TKIs+ITP was identified via Kaplan-Meier method. A P-value of less than 0.05 was viewed as a statistically significant level.
Results
A total of 53 patients were included in the study with an median age of 51 years(range, 33-81years), in which 23(43.4%) were males, 27(50.9%) were stage IVA, and 26(49.1%) were stage IVB. Among total population, 22(41.5%) were found in the left thoracic cavity, 28(52.8%) were found in the right, and 3(5.7%) were found in the bilateral. As for genetic mutation types, 34(64.2%) of them were found 19-del mutation, 20(37.7%) were found L858R mutation, and 7(13.2%) were T790M mutation. Eighteen patients(34.0%) received intrathoracic perfusion of platinum-based chemotherapy, in which 8(15.1%) received additional interleukin-2 or antiangiogenic agents. The median OS was 31 months(range, 2-84months) and 66 months(range, 3-90months) for TKIs and TKIs+ITP, respectively(P=0.039; Figure 1).
Figure 1 Kaplan-Meier curves comparing the treatment in overall survival(P=0.039) in patients with tyrosine kinase inhibitor treatment(TKIs) alone and TKI along with concomitant intrathoracic perfusion(TKIs+ITP).
Conclusion
Intrathoracic perfusion combined with TKI treatment could improve the prognosis of stage IV lung adenocarcinoma with EGFR mutation, compared to TKI treatment alone. Overall response rate(ORR), progression free survival(PFS) and subgroup analysis concerning different genetic mutation types will be carried out subsequently.
